Multilineage differentiation drives hamartoma formation in large-to-giant congenital melanocytic naevi: evidence for naevocyte multipotency.
Wei B., Zhu D., Jin J., Lai B., Gu J., Yan Y.
Animal Study, published in Br J Dermatol (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Br J Dermatol (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41746261
- DOI
- 10.1093/bjd/ljaf497
Abstract (original English)
Large-to-giant congenital melanocytic naevi (LGCMNs) often develop nodules that contain ectopic tissues (hamartomas), which are rarely observed in small-to-medium congenital melanocytic naevi (SMCMNs). The origin and mechanism of the hamartomas formed in LGCMNs remain unknown. To investigate the origin and mechanism of hamartoma formation in LGCMNs, and to evaluate the stemness and multipotency of LGCMNs. A total of 276 congenital melanocytic naevi (CMNs) of different sizes were included in this study. LGCMNs with diverse hamartomas were identified and analysed by histology and immunofluorescence. Whole-exome sequencing (WES) of matched healthy skin, LGCMN and hamartoma tissues assessed mutational overlap. RNA sequencing (RNAseq), immunohistochemistry and immunocytochemistry evaluated multipotency pathways and stem markers across CMN sizes. LGCMN and SMCMN cells were assayed for clonogenicity and induced to differentiate along osteogenic, chondrogenic, adipogenic and neurogenic lineages in vitro. Three-dimensional spheroid cultures and cell-derived xenograft (CDX) models tested LGCMN multilineage differentiation in vivo. Single-cell RNAseq (scRNAseq) of patient-derived hamartomas delineated intermediate differentiation states and active pathways. We found that LGCMN lesions harboured bone, cartilage, adipose and neural hamartomas with intermixed naevocytes. WES revealed 35-92%
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.